Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Even as new technologies transform healthcare, local leaders emphasized the importance of never losing the human touch within ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...